Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort

PURPOSE: Treatment with pembrolizumab, an anti–programmed death-1 antibody, at 10 mg/kg administered once every 2 weeks, displayed durable antitumor activity in programmed death-ligand 1 (PD-L1) –positive recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) in the KEYNOTE-...

Descripción completa

Detalles Bibliográficos
Autores principales: Chow, Laura Q.M., Haddad, Robert, Gupta, Shilpa, Mahipal, Amit, Mehra, Ranee, Tahara, Makoto, Berger, Raanan, Eder, Joseph Paul, Burtness, Barbara, Lee, Se-Hoon, Keam, Bhumsuk, Kang, Hyunseok, Muro, Kei, Weiss, Jared, Geva, Ravit, Lin, Chia-Chi, Chung, Hyun Cheol, Meister, Amy, Dolled-Filhart, Marisa, Pathiraja, Kumudu, Cheng, Jonathan D., Seiwert, Tanguy Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2016
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804896/
https://www.ncbi.nlm.nih.gov/pubmed/27646946
http://dx.doi.org/10.1200/JCO.2016.68.1478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6804896/
https://www.ncbi.nlm.nih.gov/pubmed/27646946
http://dx.doi.org/10.1200/JCO.2016.68.1478

Ejemplares similares